| Title | Author(s) | Year | View Count |
 | A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma | Yau, T; Cheng, PN; Chan, P; Chan, W; Chen, L; Yuen, J; Pang, R; Fan, ST; Poon, RT | 2012 | 95 |
 | Mapping the functional assessment of cancer therapy-general or -colorectal to SF-6D in Chinese patients with colorectal neoplasm | Wong, CKH; Lam, CLK; Rowen, D; McGhee, SM; Ma, KP; Law, WL; Poon, JTC; Chan, P; Kwong, DLW; Tsang, J | 2012 | 122 |
| The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits | Chiu, J; Tang, YF; Yao, TJ; Wong, A; Wong, H; Leung, R; Chan, P; Cheung, TT; Chan, AC; Pang, R; Fan, ST; Poon, R; Yau, T | 2012 | 80 |
 | Being active or flexible?: Role of control coping on quality of life among patients with gastrointestinal cancer | Cheng, C; Chan, TN; Chio, JH; Chan, P; Chan, AOO; Hui, WM | 2012 | 71 |
| Colon cancer in a patient with underlying aplastic anemia: A clinical challenge | Wong, H; Chan, P; Yau, TCC | 2012 | 48 |
| The cardioprotective effect of isosteviol on endothelin-1-induced hypertrophy of cultured neonatal rat cardiomyocytes | Wong, K; Chao, CC; Cheung, CW; Chan, P; Cheng, TH; Leung, YM | 2012 | 52 |
| Being active or flexible? Role of control coping on quality of life among patients with gastrointestinal cancer | Cheng, C; Chan, NY; Chio, JHM; Chan, P; Chan, AOO; Hui, WM | 2012 | 64 |
| Validity and reliability study on traditional Chinese FACT-C in Chinese patients with colorectal neoplasm | Wong, CKH; Lam, CLK; Law, WL; Poon, JTC; Chan, P; Kwong, DLW; Tsang, J | 2012 | 177 |
| Direct medical costs of care for Chinese patients with colorectal neoplasia: a health care service provider perspective | Wong, CKH; Lam, CLK; Poon, JTC; Mcghee, SM; Law, WL; Kwong, DLW; Tsang, J; Chan, P | 2012 | 193 |
| Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease | Yau, T; Wong, H; Chan, P; Yao, TJ; Pang, R; Cheung, TT; Fan, ST; Poon, RT | 2012 | 96 |
| The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (hcc) | Wong, H; Tang, YF; Yao, TJ; Chiu, J; Leung, R; Chan, P; Cheung, TT; Chan, AC; Pang, RW; Poon, R; Fan, ST; Yau, T | 2011 | 132 |
| Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics | Yau, T; Chen, PJ; Chan, P; Curtis, CM; Murphy, PS; Suttle, AB; Gauvin, J; Hodge, JP; Dar, MM; Poon, RT | 2011 | 192 |
| The outcomes of elderly patients with advanced hepatocellular carcinoma treated with single agent Sorafenib (Abstract) | Chan, P; Wong, H; Yao, TJ; Tang, VWK; Wong, H; Fan, ST; Poon, RTP; Yau, TCC | 2011 | 116 |
| Efficacy and tolerability of Sorafenib, Capecitabine and Oxaliplatin (Secox) in patients with advanced hepatocellular carcinoma: a multi-centre phase II study (Abstract) | Yau, TCC; Chan, P; Cheung, FY; Lee, AS; Yau, TK; Choo, SP; Toh, HC; Leung, AK; Wong, JS; Wong, S; Lau, J; Pang, RWC; Fan, ST; Poon, RTP | 2011 | 221 |
| Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: a prospective, open-label, phase II study | Yau, T; Leung, RC; Wong, H; Chiu, J; Chan, P; Pang, R; Fan, ST; Poon, RTP | 2011 | 162 |
| The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis | Chiu, J; Tang, YF; Yao, TJ; Wong, A; Wong, H; Leung, R; Chan, P; Cheung, TT; Poon, RTP; Fan, ST; Yau, CC | 2011 | 191 |
| Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocellular carcinoma after sorafenib failure: a prospective, open-label, phase II study (Abstract) | Yau, TCC; Leung, RCY; Wong, H; Chiu, J; Chan, P; Pang, RWC; Fan, ST; Poon, RTP | 2011 | 185 |
| Mapping the functional assessment of cancer therapy-general or -colorectal to preference-based values measured by SF-6D in patients with colorectal neoplasm | Wong, CKH; Lam, CLK; McGhee, SM; Law, WL; Poon, TCJ; Chan, P; Kwong, DLW; Tsang, J; Rowen, DL | 2011 | 55 |
| The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib | Yau, T; Yao, TJ; Chan, P; Wong, H; Pang, R; Fan, ST; Poon, RTP | 2011 | 207 |
| Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trial | Tan, VPY; Wong, WM; Cheung, TK; Lai, KC; Hung, IFN; Chan, P; Pang, R; Wong, BCY | 2011 | 190 |
|
